Browse the evidence

Visceral fat accumulation is a primary driver of cardiovascular disease in obesity, independent of BMI, through inflammatory and metabolic mechanisms.

Focus on reducing visceral fat through lifestyle changes, not just BMI. Even if your BMI is normal, high waist circumference indicates higher cardiovascular risk.

The protective effect of beneficial dietary components on all-cause mortality is partially mediated by a reduction in systemic inflammation, as measured by the Systemic Inflammation Index (SII).

While reducing inflammation is part of the benefit, it is not the whole story. The dietary components likely work through multiple pathways, including direct gut microbiome effects, not just lowering blood inflammation markers.

Women diagnosed with breast cancer can safely consume soyfoods without increasing the risk of recurrence or mortality, and post-diagnosis soy intake may be associated with a decreased risk of recurrence.

If you have had breast cancer, you can eat soyfoods. They are safe and do not increase your risk of the cancer coming back. Some studies even suggest they might help, but you shouldn't start eating them just to treat the cancer—just include them as part of a healthy diet.

GLP-1 receptor agonists provide significant cardiovascular benefits, including reduced risk of major adverse cardiovascular events (MACE) and stroke, in addition to weight loss and glycemic control.

GLP-1 agonists (like Ozempic or Victoza) do more than lower blood sugar and help with weight loss. They have been proven to reduce the risk of heart attacks, strokes, and cardiovascular death in people with Type 2 Diabetes. If you have heart disease or risk factors, these drugs may offer significant protection beyond just sugar control.

Omitting initial glucose-lowering drug treatment (GLDT) in newly diagnosed type 2 diabetes is associated with a higher 5-year risk of major adverse cardiovascular events (MACE), primarily mediated by lower initiation of statins and renin-angiotensin system inhibitors (RASi), even in patients achieving glycemic remission.

If you have newly diagnosed type 2 diabetes, even if you manage to normalize your blood sugar through diet and exercise (remission), you may still be at higher risk for heart attacks or strokes if you avoid glucose-lowering drugs. This is likely because avoiding these drugs also means you are less likely to be prescribed essential heart-protective medications like statins or blood pressure drugs. Ensure your doctor prescribes appropriate cardiovascular prevention strategies regardless of your glycemic status.

Metabolic health status (MHO vs. MUO) is a better predictor of long-term cardiovascular risk and mortality than BMI alone, with metabolically unhealthy obesity (MUO) requiring prompt intervention.

If you have obesity, ask your doctor to check your metabolic health (blood pressure, lipids, blood sugar), not just your weight. Your risk of heart disease depends more on these numbers and where you store fat (belly vs. hips) than your BMI alone. If you are metabolically unhealthy, you need prompt intervention.

Lowering blood glucose levels reverses glucose toxicity, thereby restoring beta-cell insulin secretion and enabling complete or partial remission of type 2 diabetes.

If you have Type 2 Diabetes, high blood sugar actively suppresses your pancreas's ability to make insulin. This suppression is often reversible. By aggressively lowering your blood glucose levels—through medication, intensive insulin therapy, or dietary changes—you can remove this 'glucose toxicity.' This allows your remaining beta-cells to recover function, potentially leading to remission where you no longer need medication. This is most likely if you have not had diabetes for many years and still have some beta-cell mass left.

In type 2 diabetes patients initiating insulin therapy, pre-insulin weight loss combined with rising or persistently high HbA1c is the strongest predictor of excessive post-initiation weight gain (≥5 kg).

If you are starting insulin and have lost weight recently while your blood sugar numbers were going up, expect to regain that weight. This is likely 'catch-up' weight as your body stops losing sugar through urine. It is a sign the insulin is working to correct your metabolism, not necessarily a failure of your diet. Monitor your weight, but do not let fear of this specific type of gain prevent you from starting life-saving therapy.

High-dose 2'-FL supplementation (5g/day) in older adults significantly increases serum levels of Fibroblast Growth Factor 21 (FGF21) and HDL cholesterol, while depleting octanoylcarnitine.

Older adults taking 5g of 2'-FL daily may see improvements in HDL cholesterol and levels of the hormone FGF21, which regulates lipid metabolism. These changes are associated with the bloom of Bifidobacterium in the gut. The intervention is well-tolerated.

Low serum creatinine levels in early pregnancy (10-14 weeks) are associated with a significantly higher incidence of postpartum abnormal glucose metabolism (AGM) in women with a history of gestational diabetes mellitus (GDM).

If you have a history of gestational diabetes, your early pregnancy creatinine level may predict your risk of developing persistent blood sugar issues after birth. Since creatinine reflects muscle mass, and muscle is key for processing glucose, maintaining or building muscle mass through resistance training and adequate protein intake before and during pregnancy may help mitigate this risk. Discuss your creatinine levels with your endocrinologist or obstetrician as part of your GDM management plan.

In individuals with type 2 diabetes who do not carry the haptoglobin (Hp) 2-2 phenotype, maintaining an HbA1c level below 6.5% is associated with a significantly lower risk of coronary artery disease compared to maintaining levels between 7.0% and 7.9%.

If you have type 2 diabetes and do not have the haptoglobin 2-2 genetic variant, aiming for an HbA1c below 6.5% may offer better protection against heart disease than aiming for 7.0-7.9%. This suggests that personalized glycemic targets based on genetic factors could optimize cardiovascular health.

Integrase Strand Transfer Inhibitors (INSTIs), specifically Dolutegravir (DTG) and Bictegravir (BIC), are associated with significant weight gain compared to older antiretrovirals like Efavirenz (EFV) or Protease Inhibitors.

If you are starting HIV treatment, ask your doctor about INSTIs (like Dolutegravir). They are effective but may cause weight gain, especially in women and Black individuals. If weight gain is a major concern, discuss alternatives like TDF-based regimens or older agents like Efavirenz, though these may have other side effects.

The fixed-dose extended-release combination of naltrexone and bupropion (NB-ER) is the most promising pharmacotherapy for facilitating smoking cessation while preventing post-cessation weight gain in individuals with obesity.

If you smoke and have obesity, your fear of gaining weight after quitting is valid and common. Standard cessation drugs often fail to stop this weight gain. Ask your doctor about NB-ER (naltrexone/bupropion extended-release), which targets the brain pathways for both addiction and hunger, offering the best chance to quit smoking without the associated weight gain.

Obesity increases cardiovascular risk and mortality primarily through visceral adiposity and ectopic fat deposition (pericardial/epicardial), which drive endothelial dysfunction, chronic inflammation, and atherosclerosis, independent of or additive to traditional risk factors like BMI, blood pressure, and cholesterol.

Focus on reducing visceral and ectopic fat, not just total weight. Measures like waist circumference are more predictive of heart disease risk than BMI. Lifestyle interventions, particularly aerobic exercise, can reduce visceral adipose tissue even without significant weight loss, thereby lowering cardiovascular risk.

Ethnicity-specific BMI cut-offs are required for accurate diagnosis and management of obesity-related risks, particularly for South Asian populations.

If you are of South Asian descent, be aware that your risk for Type 2 Diabetes increases at a lower BMI (around 23.9 kg/m2) compared to the standard 30 kg/m2. Discuss ethnicity-specific risk assessments with your healthcare provider.

Targeted pharmacotherapy for obesity should focus on the MC4R pathway (e.g., MC4R agonists) for patients with specific genetic defects in upstream genes like POMC, PCSK1, or LEPR.

If you have a known genetic defect affecting your hunger hormones (like POMC or MC4R deficiencies), standard diets may fail. You should ask your doctor about genetic testing. If positive, you may be eligible for targeted medications like setmelanotide (Imcivree) that specifically fix the broken pathway.

Discontinuation of GLP-1 agonist pharmacotherapy (e.g., semaglutide) leads to rapid weight regain, necessitating indefinite long-term treatment for maintenance.

If you use GLP-1 medications like semaglutide for weight loss, understand that stopping them will likely cause you to regain the weight quickly. These drugs treat obesity as a chronic condition, meaning you likely need to stay on them long-term to keep the weight off, regardless of cost or insurance hurdles.

Newer GLP-1 and dual-agonist obesity medications produce significant weight loss (15-21%) and metabolic benefits, but discontinuation leads to weight regain.

Use GLP-1 medications as a long-term tool for weight management, not a short-term fix. Be prepared to continue treatment to maintain weight loss, as stopping often leads to regain.

GLP-1 analogs (e.g., Semaglutide, Liraglutide) and dual agonists (Tirzepatide) produce significant weight loss (up to 21%) but are associated with high costs, lifelong administration requirements, and gastrointestinal side effects that may drive patients toward complementary therapies.

GLP-1 drugs (Semaglutide, Tirzepatide) are highly effective for weight loss (15-21%), but they are expensive, require lifelong injections, and cause GI side effects. If you experience side effects or cannot afford long-term use, you are not alone; many patients seek complementary therapies like TCM to manage weight and side effects.

In patients with advanced chronic liver disease (ACLD), achieving >10% body weight loss through therapeutic lifestyle interventions significantly reduces portal hypertension and improves survival, although this magnitude of weight loss is difficult to sustain long-term.

For ACLD patients, aiming for >10% weight loss via diet and exercise can significantly lower portal pressure and improve survival. However, this is hard to maintain; consider medical weight loss aids if lifestyle changes alone fail to sustain the loss.

New generation obesity medications (GLP-1/GIP agonists) achieve mean weight loss of 15–25% over 68–72 weeks, narrowing the efficacy gap between medical and surgical management of obesity.

New GLP-1/GIP medications like semaglutide (2.4mg weekly) and tirzepatide are highly effective, producing 15-25% weight loss over ~1.5 years. This efficacy is now comparable to surgery, making medication a primary, not just secondary, option for obesity treatment.

Poor glycemic control exacerbates dyslipidemia in diabetes by increasing hepatic VLDL production and decreasing HDL levels, while improvements in glycemic control can reverse these lipid abnormalities.

For people with diabetes, keeping blood sugar levels in range is important, but it is not enough to protect your heart. Even if your A1C is good, you likely still have abnormal cholesterol levels, specifically high triglycerides and low HDL. This is because diabetes changes how your liver processes fats. You need to monitor your lipid profile separately and likely take medication (like statins) to manage cardiovascular risk, regardless of how well your blood sugar is controlled.

A Body Shape Index (ABSI) is associated with incident cardiovascular disease, with the highest risk observed in individuals with high ABSI combined with high RCII.

For adults over 45, monitoring your Body Shape Index (ABSI) alongside your cholesterol and inflammation levels (RCII) provides a more accurate assessment of heart disease risk than weight alone. If you have a high ABSI and high RCII, you are in a high-risk subgroup that may benefit from intensified lifestyle interventions.

Ultra rapid lispro (URLi) administered as a bolus with basal insulin improves postprandial glucose excursions (PPGE) after breakfast more effectively than standard insulin lispro in adults with type 2 diabetes, while maintaining non-inferior HbA1c reduction and similar safety profiles regarding hypoglycemia and weight gain.

If you have Type 2 Diabetes and struggle with high blood sugar after meals, especially breakfast, ask your doctor about Ultra Rapid Lispro (URLi). It is taken exactly like your current rapid-acting insulin (just before eating) but absorbs faster to better match your food. This can significantly reduce the sharp blood sugar spikes after breakfast without increasing your risk of low blood sugar or weight gain compared to standard insulin lispro.